<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-70 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-70</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-70</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-37e58f434f3ea7a6b365a88b1dd0a45c8ac99242</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/37e58f434f3ea7a6b365a88b1dd0a45c8ac99242" target="_blank">Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial</a></p>
                <p><strong>Paper Venue:</strong> Nature Medicine</p>
                <p><strong>Paper TL;DR:</strong> Patients with resected stage IIB/C melanoma who received adjuvant nivolumab had significantly prolonged recurrence-free survival compared to placebo-treated patients, providing another treatment option for this population, according to this pre-specified interim analysis.</p>
                <p><strong>Paper Abstract:</strong> In this pre-specified interim analysis, patients with resected stage IIB/C melanoma who received adjuvant nivolumab had significantly prolonged recurrence-free survival compared to placebo-treated patients, providing another treatment option for this population. Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The primary endpoint was investigator-assessed recurrence-free survival (RFS). Secondary endpoints included distant metastasis-free survival (DMFS) and safety. At 7.8 months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR) = 0.42; 95% confidence interval (CI): 0.30–0.59; P  < 0.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR = 0.47; 95% CI: 0.30–0.72). Treatment-related grade 3/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients. One treatment-related death (0.2%) occurred with nivolumab. Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB/C melanoma. ClinicalTrials.gov identifier: NCT04099251 .</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e70.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e70.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 76K</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Adjuvant nivolumab in resected stage IIB/C melanoma: the randomized, phase 3 CheckMate 76K trial</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A double-blind, randomized phase 3 trial that randomized 790 patients with completely resected stage IIB/C melanoma 2:1 to receive adjuvant nivolumab 480 mg IV every 4 weeks versus placebo for a protocol-specified fixed duration of 12 months, assessing recurrence-free survival (primary) and distant metastasis-free survival (secondary).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 76K</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage IIB/C (completely resected)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>fixed 12 months (nivolumab 480 mg IV every 4 weeks) or until recurrence, unacceptable toxicity, or withdrawal</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td>11.0 months (median; range 0–12.1 months); median of 12 doses (range 1–14)</td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Not applicable for typical CR/PR/SD reporting (adjuvant setting); efficacy assessed by recurrence events (local/regional/distant), new primary melanomas, and death (RFS) and first distant recurrence or death (DMFS).</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>No within-trial comparison of different treatment durations was performed; protocol used a fixed 12-month adjuvant course. Overall efficacy for the fixed 12-month strategy: RFS HR = 0.42 (95% CI: 0.30–0.59; P < 0.0001) favoring nivolumab; 12-month RFS 89.0% (95% CI: 85.6–91.6) with nivolumab vs 79.4% (95% CI: 73.5–84.1) with placebo. DMFS HR = 0.47 (95% CI: 0.30–0.72). Absolute distant recurrence at data cutoff: 4.9% (26/526) nivolumab vs 11.7% (31/264) placebo.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>No analyses stratifying toxicity by duration on treatment were reported. Overall (blinded phase) treatment-related adverse events (≤30 days after last dose): any grade 82.6% (433/524) nivolumab vs 53.8% (142/264) placebo; grade 3–4 10.3% (54/524) vs 2.3% (6/264). Immune-mediated endocrine events required hormone replacement in 14.9% (78/524) nivolumab patients (primarily thyroid).</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td>By data cutoff: 49.0% (257/524) of nivolumab-treated patients completed blinded-phase treatment and 12.2% (64/524) were still on treatment; the most common reasons for stopping nivolumab before completing blinded treatment were study drug toxicity 17.9% (94/524), disease recurrence 5.0% (26/524) and patient request 5.5% (29/524). Treatment-related adverse events led to discontinuation in 14.7% (77/524) of nivolumab-treated patients. Overall any-adverse-event leading to discontinuation: 17.4% (91/524).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>The trial used and demonstrates clinical benefit for a fixed 1-year (12-month) adjuvant nivolumab regimen; the authors support adjuvant nivolumab for 1 year in this population but note that the study did not compare alternative durations and that further study of early discontinuation/optimal duration is warranted.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e70.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e70.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced phase 3 randomized trial of adjuvant pembrolizumab versus placebo in resected stage IIB/C melanoma that demonstrated an RFS benefit and provided regulatory support for adjuvant anti-PD-1 therapy in this population; discussed in the paper for contextual comparison.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage IIB/C (completely resected) — referenced</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Not reported in this paper; referenced trial reported RFS and DMFS endpoints.</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>This paper cites KEYNOTE-716 as demonstrating RFS improvement with pembrolizumab versus placebo (HR = 0.65; 95% CI: 0.46–0.92) and DMFS improvement (reported elsewhere); no duration-comparison data are provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e70.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e70.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801 trial (neoadjuvant + adjuvant vs adjuvant-only pembrolizumab in resectable advanced melanoma)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced phase 2 trial that compared perioperative (neoadjuvant + adjuvant) pembrolizumab versus adjuvant-only pembrolizumab in patients with resectable stage IIIB–D or stage IV (macroscopic nodal) melanoma, reporting prolonged event-free survival for the perioperative strategy; mentioned as context but not part of CheckMate 76K.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant + adjuvant versus adjuvant-only in resectable stage IIIB–D/IV (macroscopic nodal) disease — referenced</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Not detailed in this paper; referenced outcome was event-free survival benefit for perioperative approach.</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Mentioned as evidence that combining neoadjuvant and adjuvant anti-PD-1 (perioperative) prolonged event-free survival compared with adjuvant-only in a different (node-positive/macroscopic) patient population; CheckMate 76K authors note these results cannot be directly extrapolated to stage IIB/C.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial <em>(Rating: 2)</em></li>
                <li>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma <em>(Rating: 2)</em></li>
                <li>Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325/KEYNOTE-054) <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>